-
Something wrong with this record ?
Management of Adult Patients With Drug Reaction With Eosinophilia and Systemic Symptoms: A Delphi-Based International Consensus
MC. Brüggen, S. Walsh, MM. Ameri, N. Anasiewicz, E. Maverakis, LE. French, S. Ingen-Housz-Oro, DRESS Delphi consensus group, R. Abe, M. Ardern-Jones, H. Assier, A. Barbaud, B. Bensaid, W. Bernal, C. Bernier, A. Brassard, E. Brezinová, R. Cabañas,...
Language English Country United States
Document type Journal Article
- MeSH
- Delphi Technique MeSH
- Adult MeSH
- Eosinophilia * chemically induced diagnosis therapy MeSH
- Consensus MeSH
- Drug Hypersensitivity Syndrome * diagnosis etiology therapy MeSH
- Humans MeSH
- Surveys and Questionnaires MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
IMPORTANCE: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but potentially fatal drug hypersensitivity reaction. To our knowledge, there is no international consensus on its severity assessment and treatment. OBJECTIVE: To reach an international, Delphi-based multinational expert consensus on the diagnostic workup, severity assessment, and treatment of patients with DRESS. DESIGN, SETTING, AND PARTICIPANTS: The Delphi method was used to assess 100 statements related to baseline workup, evaluation of severity, acute phase, and postacute management of DRESS. Fifty-seven international experts in DRESS were invited, and 54 participated in the survey, which took place from July to September 2022. MAIN OUTCOMES/MEASURES: The degree of agreement was calculated with the RAND-UCLA Appropriateness Method. Consensus was defined as a statement with a median appropriateness value of 7 or higher (appropriate) and a disagreement index of lower than 1. RESULTS: In the first Delphi round, consensus was reached on 82 statements. Thirteen statements were revised and assessed in a second round. A consensus was reached for 93 statements overall. The experts agreed on a set of basic diagnostic workup procedures as well as severity- and organ-specific further investigations. They reached a consensus on severity assessment (mild, moderate, and severe) based on the extent of liver, kidney, and blood involvement and the damage of other organs. The panel agreed on the main lines of DRESS management according to these severity grades. General recommendations were generated on the postacute phase follow-up of patients with DRESS and the allergological workup. CONCLUSIONS AND RELEVANCE: This Delphi exercise represents, to our knowledge, the first international expert consensus on diagnostic workup, severity assessment, and management of DRESS. This should support clinicians in the diagnosis and management of DRESS and constitute the basis for development of future guidelines.
Center for Biomedical Research Network on Rare Diseases Madrid Spain
Center of Rare Diseases IDI IRCCS Rome Italy
Christine Kühne Center for Allergy Research and Education Davos Switzerland
Department of Allergy La Paz University Hospital IdiPAZ Madrid Spain
Department of Dermatology and Allergology Tenon Hospital Sorbonne Universite Paris France
Department of Dermatology and Allergy Hannover Medical School Hannover Germany
Department of Dermatology Bichat Claude Bernard Hospital Paris Diderot University Paris France
Department of Dermatology Brigham and Women's Hospital Harvard Medical School Boston Massachusetts
Department of Dermatology Emek Medical Center Afula Israel
Department of Dermatology Keck School of Medicine University of Southern California Los Angeles
Department of Dermatology King's College Hospital London England United Kingdom
Department of Dermatology Kyorin University School of Medicine Mitaka Japan
Department of Dermatology Lyon Natecia Hospital Lyon France
Department of Dermatology Miller School of Medicine University of Miami Miami Florida
Department of Dermatology Nara Medical University Kashihara Japan
Department of Dermatology Ospedale San Bortolo Vicenza Italy
Department of Dermatology Perelman School of Medicine University of Pennsylvania Philadelphia
Department of Dermatology Singapore General Hospital Singapore Singapore
Department of Dermatology The Ohio State University Columbus Ohio
Department of Dermatology University Hospital Lübeck Lübeck Germany
Department of Dermatology University Hospital Nantes Nantes France
Department of Dermatology University Hospital of Bordeaux Bordeaux France
Department of Dermatology University Hospital of Zurich Zurich Switzerland
Department of Dermatology University of California Davis Sacramento California
Department of Dermatology University of California San Francisco
Department of Dermatology University of Debrecen Debrecen Hungary
Department of Dermatology University of Kansas Kansas City
Department of Medicine and Pharmacology Vanderbilt University Medical Center Nashville Tennessee
Department of Oral Medicine Guy's and St Thomas' NHS Foundation Trust London England United Kingdom
Division of Dermatology Sunnybrook Health Sciences Centre Toronto Ontario Canada
Faculty of Medicine University of Zurich Zurich Switzerland
Images in Dermatology Editor JAMA Dermatology
PIELenRed Consortium Madrid Spain
Regional Pharmacovigilance Centre Pitié Salpêtrière Hospital APHP Sorbonne Université Paris France
Ruth and Bruce Rappaport Faculty of Medicine Technion Israel Institute of Technology Haifa Israel
ToxiTEN group European Reference Network for Rare Skin Diseases Paris France
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24007802
- 003
- CZ-PrNML
- 005
- 20240423160300.0
- 007
- ta
- 008
- 240412s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1001/jamadermatol.2023.4450 $2 doi
- 035 __
- $a (PubMed)37966824
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Brüggen, Marie-Charlotte $u Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland $u Faculty of Medicine, University of Zurich, Zurich, Switzerland $u Christine Kühne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland $u ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France
- 245 10
- $a Management of Adult Patients With Drug Reaction With Eosinophilia and Systemic Symptoms: A Delphi-Based International Consensus / $c MC. Brüggen, S. Walsh, MM. Ameri, N. Anasiewicz, E. Maverakis, LE. French, S. Ingen-Housz-Oro, DRESS Delphi consensus group, R. Abe, M. Ardern-Jones, H. Assier, A. Barbaud, B. Bensaid, W. Bernal, C. Bernier, A. Brassard, E. Brezinová, R. Cabañas, A. Cardones, CY. Chu, SL. Chua, V. Descamps, B. Didona, SJ. Divito, R. Dodiuk-Gad, S. Elman, K. Gaspar, CG. Mortz, N. Hama, HY. Lee, B. Horváth, L. Jörg, BH. Kaffenberger, V. Kucinskiene, B. Lebrun-Vignes, RJ. Lehloenya, D. Meyersburg, R. Micheletti, B. Milpied, F. Miyagawa, A. Mostaghimi, M. Nägeli, L. Naldi, E. Oppel, EJ. Phillips, T. Pirani, A. Ranki, T. Mälkönen, M. Rosenbach, C. Salavastru, D. Staumont-Salle, H. Sandberg, J. Setterfield, K. Shinkai, T. Shiohara, A. Soria, D. Tartar, GS. Tiplica, S. Traidl, A. Vorobyev, C. von Wachter, S. Worswick, YT. Cho
- 520 9_
- $a IMPORTANCE: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but potentially fatal drug hypersensitivity reaction. To our knowledge, there is no international consensus on its severity assessment and treatment. OBJECTIVE: To reach an international, Delphi-based multinational expert consensus on the diagnostic workup, severity assessment, and treatment of patients with DRESS. DESIGN, SETTING, AND PARTICIPANTS: The Delphi method was used to assess 100 statements related to baseline workup, evaluation of severity, acute phase, and postacute management of DRESS. Fifty-seven international experts in DRESS were invited, and 54 participated in the survey, which took place from July to September 2022. MAIN OUTCOMES/MEASURES: The degree of agreement was calculated with the RAND-UCLA Appropriateness Method. Consensus was defined as a statement with a median appropriateness value of 7 or higher (appropriate) and a disagreement index of lower than 1. RESULTS: In the first Delphi round, consensus was reached on 82 statements. Thirteen statements were revised and assessed in a second round. A consensus was reached for 93 statements overall. The experts agreed on a set of basic diagnostic workup procedures as well as severity- and organ-specific further investigations. They reached a consensus on severity assessment (mild, moderate, and severe) based on the extent of liver, kidney, and blood involvement and the damage of other organs. The panel agreed on the main lines of DRESS management according to these severity grades. General recommendations were generated on the postacute phase follow-up of patients with DRESS and the allergological workup. CONCLUSIONS AND RELEVANCE: This Delphi exercise represents, to our knowledge, the first international expert consensus on diagnostic workup, severity assessment, and management of DRESS. This should support clinicians in the diagnosis and management of DRESS and constitute the basis for development of future guidelines.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a lékový hypersenzitivní syndrom $x diagnóza $x etiologie $x terapie $7 D063926
- 650 _2
- $a konsensus $7 D032921
- 650 _2
- $a delfská metoda $7 D003697
- 650 12
- $a eozinofilie $x chemicky indukované $x diagnóza $x terapie $7 D004802
- 650 _2
- $a průzkumy a dotazníky $7 D011795
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Walsh, Sarah $u ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France $u Department of Dermatology, King's College Hospital, London, England, United Kingdom
- 700 1_
- $a Ameri, M Milad $u Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland $u Faculty of Medicine, University of Zurich, Zurich, Switzerland $u Christine Kühne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland
- 700 1_
- $a Anasiewicz, Natalie $u Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
- 700 1_
- $a Maverakis, Emanual $u Department of Dermatology, University of California, Davis, Sacramento, California
- 700 1_
- $a French, Lars E $u ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France $u Department of Dermatology and Allergy, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany $u Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, Florida
- 700 1_
- $a Ingen-Housz-Oro, Saskia $u ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France $u Department of Dermatology, Henri Mondor University Hospital, University of Paris-Est Créteil, Créteil, France $u Toxic Bullous Dermatoses TOXIBUL Reference Center, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France $u Univ Paris Est Créteil EpiDermE, Créteil, France
- 700 1_
- $a Abe, Richiiro $u Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
- 700 1_
- $a Ardern-Jones, Michael $u Department of Dermatology, Clinical Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, England, United Kingdom
- 700 1_
- $a Assier, Haudrey $u Department of Dermatology, Henri Mondor University Hospital, University of Paris-Est Créteil, Créteil, France
- 700 1_
- $a Barbaud, Annick $u Sorbonne Université, INSERM, Institut Pierre Louis d'Epidemiologie et de Sante Publique, AP-HP Sorbonne Universite, Tenon Hospital, Department of Dermatology and Allergology, Paris, France
- 700 1_
- $a Bensaid, Benoit $u Department of Dermatology, Lyon Natecia Hospital, Lyon, France
- 700 1_
- $a Bernal, William $u Liver Intensive Therapy Unit, King's Critical Care, King's College Hospital, London, England, United Kingdom
- 700 1_
- $a Bernier, Claire $u Department of Dermatology, University Hospital Nantes, Nantes, France
- 700 1_
- $a Brassard, Alain $u Department of Dermatology, University of California, Davis, Sacramento, California
- 700 1_
- $a Brezinová, Eva $u ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France $u Department of Dermatovenereology, St Anne's Faculty Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Cabañas, Rosario $u Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain $u PIELenRed Consortium, Madrid, Spain $u Center for Biomedical Research Network on Rare Diseases (CIBERER U754), Madrid, Spain
- 700 1_
- $a Cardones, Adela $u Department of Dermatology, University of Kansas, Kansas City
- 700 1_
- $a Chu, Chia-Yu $u Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
- 700 1_
- $a Chua, Ser-Ling $u ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France $u Department of Dermatology, University of California, San Francisco
- 700 1_
- $a Descamps, Vincent $u Department of Dermatology, Bichat-Claude Bernard Hospital, Paris Diderot University, Paris, France
- 700 1_
- $a Didona, Biagio $u ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France $u Center of Rare Diseases IDI-IRCCS, Rome, Italy
- 700 1_
- $a Divito, Sherrie Jill $u Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
- 700 1_
- $a Dodiuk-Gad, Roni $u Department of Dermatology, Emek Medical Center, Afula, Israel $u Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada $u Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
- 700 1_
- $a Elman, Scott $u Department of Dermatology, Miller School of Medicine, University of Miami, Miami, Florida
- 700 1_
- $a Gaspar, Krisztian $u Department of Dermatology, University of Debrecen, Debrecen, Hungary
- 700 1_
- $a Mortz, Charlotte G $u Department of Dermatology and Allergy Center, Odense University Hospital, University of Southern Denmark, Odense, Denmark
- 700 1_
- $a Hama, Natsumi $u Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
- 700 1_
- $a Lee, Haur Yueh $u Department of Dermatology, Singapore General Hospital, Singapore, Singapore
- 700 1_
- $a Horváth, Barbara $u Center for Blistering Diseases, Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
- 700 1_
- $a Jörg, Lukas $u Division of Allergology and Clinical Immunology, Department of Pneumology and Allergology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
- 700 1_
- $a Kaffenberger, Benjamin H $u Department of Dermatology, The Ohio State University, Columbus, Ohio
- 700 1_
- $a Kucinskiene, Vesta $u ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France $u Department of Skin and Venereal Diseases, Lithuanian University of Health Sciences (LUHS), Hospital of LUHS Kauno Klinikos, Kaunas, Lithuania
- 700 1_
- $a Lebrun-Vignes, Bénédicte $u Regional Pharmacovigilance Centre, Pitié-Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France
- 700 1_
- $a Lehloenya, Rannakoe J $u Department of Paediatric Dermatology, Colentina University Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Meyersburg, Damian $u ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France $u Department of Dermatology and Allergology, University Hospital Salzburg of the Paracelsus Medical University, Salzburg, Austria
- 700 1_
- $a Micheletti, Robert $u Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia $u Images in Dermatology Editor, JAMA Dermatology
- 700 1_
- $a Milpied, Brigitte $u ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France $u Toxic Bullous Dermatoses TOXIBUL Reference Center, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France $u Department of Dermatology, University Hospital of Bordeaux, Bordeaux, France
- 700 1_
- $a Miyagawa, Fumi $u Department of Dermatology, Nara Medical University, Kashihara, Japan
- 700 1_
- $a Mostaghimi, Arash $u Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
- 700 1_
- $a Nägeli, Mirjam $u Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
- 700 1_
- $a Naldi, Luigi $u Department of Dermatology, Ospedale San Bortolo, Vicenza, Italy
- 700 1_
- $a Oppel, Eva $u Department of Dermatology and Allergy, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany
- 700 1_
- $a Phillips, Elizabeth J $u Department of Medicine and Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee
- 700 1_
- $a Pirani, Tasneem $u Liver Intensive Therapy Unit, King's Critical Care, King's College Hospital, London, England, United Kingdom
- 700 1_
- $a Ranki, Annamari $u ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France $u Department of Skin and Allergic Diseases, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
- 700 1_
- $a Mälkönen, Tarja $u Department of Skin and Allergic Diseases, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
- 700 1_
- $a Rosenbach, Misha $u Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia
- 700 1_
- $a Salavastru, Carmen $u ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France $u Department of Paediatric Dermatology, Colentina University Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Staumont-Salle, Delphine $u CHU Lille, Department of Dermatology, Univ Lille, INSERM U1286, Lille Inflammation Translational Research Institute (INFINITE) F-59000, Lille, France
- 700 1_
- $a Sandberg, Heidi $u Department of Skin and Allergic Diseases, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
- 700 1_
- $a Setterfield, Jane $u Department of Oral Medicine, Guy's and St Thomas' NHS Foundation Trust, London, England, United Kingdom
- 700 1_
- $a Shinkai, Kanade $u Department of Dermatology, University of California, San Francisco $u Editor, JAMA Dermatology
- 700 1_
- $a Shiohara, Tetsuo $u Department of Dermatology, Kyorin University School of Medicine, Mitaka, Japan
- 700 1_
- $a Soria, Angele $u Department of Dermatology and Allergology, Tenon Hospital, Sorbonne Universite, Paris, France
- 700 1_
- $a Tartar, Danielle $u Department of Dermatology, University of California, Davis, Sacramento, California
- 700 1_
- $a Tiplica, George-Sorin $u ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France $u Department of Dermatology II, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Traidl, Stephan $u Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland $u Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany
- 700 1_
- $a Vorobyev, Artem $u Department of Dermatology, University Hospital Lübeck, Lübeck, Germany
- 700 1_
- $a von Wachter, Camilla $u Faculty of Medicine, University of Zurich, Zurich, Switzerland
- 700 1_
- $a Worswick, Scott $u Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles
- 700 1_
- $a Cho, Yung-Tsu $u Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
- 710 2_
- $a DRESS Delphi consensus group
- 773 0_
- $w MED00180925 $t JAMA dermatology $x 2168-6084 $g Roč. 160, č. 1 (2024), s. 37-44
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37966824 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423160256 $b ABA008
- 999 __
- $a ok $b bmc $g 2081662 $s 1217569
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 160 $c 1 $d 37-44 $e 20240101 $i 2168-6084 $m JAMA dermatology $n JAMA Dermatol $x MED00180925
- LZP __
- $a Pubmed-20240412
